Communiqués Karyopharm Therapeutics Inc.

Actions

KPTI

US48576U2050

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Après clôture 01:28:13
1,920 ^USD	-72,61%		2,155	+12,24%

31/07	Les plus fortes baisses à la mi-journée	MT
31/07	KARYOPHARM THERAPEUTICS INC. : Baird abaisse son opinion à neutre	ZM

Communiqués

30/07	Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway	PR
30/07	Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer	PR
01/07	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
02/06	Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026	PR
02/06	Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology	PR
01/06	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PR
01/06	Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation	PR
28/05	Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference	PR
18/05	Karyopharm Therapeutics : Corporate Presentation	PU
14/05	Karyopharm Therapeutics : 1Q26 Earnings Presentation	PU
14/05	Karyopharm Therapeutics: Q1 Earnings Snapshot	AQ
14/05	Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment	PR
12/05	Karyopharm to Participate at Upcoming Investor Conferences	PR
07/05	Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026	PR
21/04	Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting	PR
16/04	Karyopharm Therapeutics : Corporate Presentation	PU
24/03	Karyopharm Announces $30 Million Private Placement with RA Capital	PR
24/03	Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction	PR
02/03	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
12/02	Karyopharm Therapeutics : Corporate Presentation	PU
12/02	Karyopharm Therapeutics : 4Q25 Earnings Presentation	PU
12/02	Karyopharm Therapeutics: Q4 Earnings Snapshot	AQ
12/02	Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress	PR
05/02	Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026	PR
03/02	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ